10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Danish biotech Genmab has announced topline results from the Phase III MAIA study of daratumumab in combination with lenalidomide and dexamethasone (DRd) versus the latter two alone, in front-line multiple myeloma. 30 October 2018
UCB has sustained its stable rate of growth and remains on target to meet its 2018 expectations, according to its results from the first nine months of the year. 30 October 2018
AMO Pharma has announced an update on results of the recently-completed TIDE study of AMO-02 (tideglusib) in treatment of autism spectrum disorder (ASD) at the 65th Annual Meeting of the American Academy of Child and Adolescent Psychiatry in Seattle, Washington, USA. 30 October 2018
Japanese drugmaker Kissei Pharmaceutical has acquired exclusive rights to develop and commercialize Tavalisse (fostamatinib disodium) in all current and potential indications in Japan, China, Taiwan and the Republic of Korea. 29 October 2018
Two major new listings on the Australian Pharmaceutical Benefits Scheme (PBS) have the potential to extend the lives of Australians with advanced lung cancer and those at risk of a heart attack, saving patients up to nearly A$190,000 ($135,714) a year. 29 October 2018
Swiss pharma giant Novartis has announced additional brolucizumab Phase III results from year two that reaffirmed its positive year one findings. 29 October 2018
Additional data from a Phase II trial on a drug being developed by Japan's Eisai and US biotech Biogen has failed to win over doubters that this could be the long-awaited answer for a step forward in Alzheimer’s. 26 October 2018
US biopharma firm AbbVie will assume full development and commercial responsibility for its collaboration with Belgo-Dutch biotech Galapagos to discover and develop new therapies to treat cystic fibrosis (CF). 26 October 2018
Regeneron Pharmaceuticals announced positive Phase III trial news on its ophthalmology drug Eylea (aflibercept) in diabetic eye disease on Thursday. 26 October 2018
Sales recorded by US biotech giant Gilead Sciences in the third quarter beat analysts’ expectations but were still down on the same period of 2017. 26 October 2018
Melbourne, Australia-headquartered Cancer Therapeutics CRC (CTx) has announced a two-year research collaboration and a license agreement with Pfizer. 26 October 2018
US biotech major Celgene today posted third-quarter 2018 financials, showing that total revenues leapt 18.4% to $3.89 billion, so beating analysts’ estimates of $3.85 billion. 25 October 2018
Amgen said yesterday that it is making its PCSK-9 inhibitor Repatha (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price. 25 October 2018
New Jersey, USA-based Merck & Co has announced strong third quarter financial results, with global revenues up 5% on the same period last year, at $10.8 billion, in line with analysts’ expectations. 25 October 2018
Ireland-based rare diseases specialist Shire has filed its second submission to the US Food and Drug Administration for its new plasma manufacturing facility near Covington, Georgia. 25 October 2018
Danish biopharma Forward Pharma says it is considering its options after the US Court of Appeals for the Federal Circuit denied the company rights to royalties relating to the blockbuster multiple sclerosis drug Tecfidera (dimethyl fumarate). 25 October 2018